Your browser is no longer supported. Please, upgrade your browser.
argenx SE
Index- P/E- EPS (ttm)-7.00 Insider Own- Shs Outstand52.81M Perf Week-5.22%
Market Cap14.58B Forward P/E- EPS next Y-18.85 Insider Trans- Shs Float50.94M Perf Month-1.24%
Income-367.70M PEG- EPS next Q-4.45 Inst Own55.70% Short Float1.97% Perf Quarter-18.00%
Sales478.90M P/S30.45 EPS this Y-176.00% Inst Trans-0.24% Short Ratio5.66 Perf Half Y-1.04%
Book/sh28.68 P/B9.63 EPS next Y-85.60% ROA- Target Price350.41 Perf Year4.00%
Cash/sh- P/C- EPS next 5Y35.00% ROE- 52W Range248.21 - 382.15 Perf YTD-6.12%
Dividend- P/FCF- EPS past 5Y- ROI-25.00% 52W High-27.38% Beta0.90
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.81% ATR9.44
Employees336 Current Ratio- Sales Q/Q-90.00% Oper. Margin-24.60% RSI (14)35.56 Volatility3.18% 2.80%
OptionableYes Debt/Eq- EPS Q/Q-4.90% Profit Margin-44.00% Rel Volume2.35 Prev Close276.10
ShortableYes LT Debt/Eq- EarningsOct 28 BMO Payout- Avg Volume177.23K Price277.52
Recom2.10 SMA20-8.35% SMA50-7.55% SMA200-8.43% Volume251,266 Change0.51%
Nov-29-21Upgrade Piper Sandler Neutral → Overweight $250 → $354
Oct-29-21Upgrade Guggenheim Neutral → Buy $330
Oct-28-21Upgrade Raymond James Outperform → Strong Buy $390
Oct-07-21Initiated Jefferies Buy $362
Sep-23-21Upgrade Redburn Neutral → Buy
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $351
Jul-23-21Initiated Deutsche Bank Hold
Jul-19-21Resumed Wolfe Research Outperform
Jun-18-21Initiated UBS Buy $390
Jun-04-21Resumed Robert W. Baird Outperform $340 → $346
May-10-21Upgrade H.C. Wainwright Neutral → Buy $320 → $400
Apr-23-21Initiated Redburn Neutral
Mar-05-21Reiterated H.C. Wainwright Neutral $265 → $320
Feb-02-21Downgrade Piper Sandler Overweight → Neutral $303
Jan-04-21Downgrade Guggenheim Buy → Neutral
Aug-25-20Initiated Raymond James Outperform $257
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-29-20Initiated H.C. Wainwright Neutral $272
Feb-10-20Initiated BofA/Merrill Buy
Nov-05-19Initiated Credit Suisse Neutral $137
Nov-10-21 01:00AM  
Oct-28-21 01:00AM  
Oct-21-21 01:00AM  
Oct-18-21 05:38AM  
Oct-08-21 01:00AM  
Sep-27-21 07:53AM  
Sep-24-21 07:51PM  
Sep-06-21 01:26PM  
Sep-03-21 01:00AM  
Aug-25-21 01:00AM  
Aug-04-21 01:00AM  
Jul-29-21 01:00AM  
Jul-22-21 01:00AM  
Jul-14-21 01:00AM  
Jul-13-21 10:15AM  
Jun-16-21 06:30PM  
Jun-15-21 08:17AM  
Jun-09-21 03:53PM  
Jun-08-21 11:09AM  
Jun-07-21 09:13AM  
Jun-01-21 04:01AM  
May-15-21 11:30AM  
May-14-21 06:45AM  
May-11-21 05:00AM  
May-10-21 11:30PM  
May-07-21 01:00AM  
Apr-28-21 01:00AM  
Mar-30-21 04:00PM  
Mar-04-21 12:30PM  
Mar-02-21 02:00AM  
Feb-25-21 01:00AM  
Feb-05-21 04:01PM  
Feb-04-21 01:00AM  
Feb-02-21 10:15PM  
Feb-01-21 04:01PM  
Jan-08-21 01:00AM  
Jan-07-21 08:20AM  
Jan-06-21 04:01PM  
Jan-04-21 01:00AM  
Dec-19-20 09:32PM  
Dec-14-20 10:12AM  
Nov-23-20 01:00AM  
Nov-17-20 07:00AM  
Nov-09-20 01:00AM  
Nov-03-20 04:14PM  
Oct-22-20 12:30PM  
Oct-15-20 01:00AM  
Oct-06-20 08:24AM  
Oct-05-20 01:00AM  
Sep-16-20 04:53PM  
Sep-02-20 01:00AM  
Aug-04-20 01:00AM  
Jul-30-20 01:00AM  
Jul-29-20 01:46PM  
Jul-20-20 12:15PM  
Jul-01-20 09:24AM  
Jun-15-20 11:09AM  
Jun-01-20 04:00PM  
May-29-20 01:00AM  
May-28-20 12:15AM  
May-27-20 10:08AM  
May-26-20 04:01PM  
May-14-20 03:30PM  
May-12-20 09:52AM  
May-11-20 05:22AM  
May-08-20 11:46AM  
Mar-22-20 10:18PM  
Feb-27-20 08:09AM  
Feb-26-20 08:57AM  
Feb-09-20 03:01AM  
Jan-07-20 08:40AM  
Dec-29-19 09:40PM  
Dec-07-19 08:02AM  
Nov-22-19 03:22PM  
Nov-12-19 04:00PM  
Nov-10-19 02:52AM  
Nov-08-19 01:00AM  
Nov-06-19 10:45PM  
Oct-24-19 01:00AM  
Oct-14-19 10:14PM  
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.A.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.